A low-dose combination oral contraceptive. Experience with 1,700 women treated for 22,489 cycles.
A multicenter study was conducted to evaluate the efficacy and acceptability of a combination oral contraceptive containing norgestrel, 0.3 mg, and ethinyl estradiol, 0.03 mg. A total of 1,700 women were treated for 22,489 cycles. Only two pregnancies occurred (Pearl index, 0.20 per 100 woman-years). Cycle control was excellent, and the incidence of breakthrough bleeding, spotting and amenorrhea was low as compared to other reported series of similar low-dose combination contraceptives. No serious side effects were reported, and the drug had no demonstrable adverse effects on weight and blood pressure. The use of this low-dose oral contraceptive appears to provide effective birth control with a high laboratory index of safety and low incidence of side effects.
D000293:Adolescent; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002986:Clinical Trials as Topic; D003276:Contraceptives, Oral / Q000009:adverse effects; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects; D004997:Ethinyl Estradiol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008598:Menstruation / Q000187:drug effects; D009644:Norgestrel / Q000008:administration & dosage*; D011247:Pregnancy
D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D009644:Norgestrel; D004997:Ethinyl Estradiol